These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 23662788)

  • 21. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M; Cordoro KM
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.
    Cargill M; Schrodi SJ; Chang M; Garcia VE; Brandon R; Callis KP; Matsunami N; Ardlie KG; Civello D; Catanese JJ; Leong DU; Panko JM; McAllister LB; Hansen CB; Papenfuss J; Prescott SM; White TJ; Leppert MF; Krueger GG; Begovich AB
    Am J Hum Genet; 2007 Feb; 80(2):273-90. PubMed ID: 17236132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
    Batalla A; Coto E; González-Fernández D; González-Lara L; Gómez J; Santos-Juanes J; Queiro R; Coto-Segura P
    Pharmacogenet Genomics; 2015 Jun; 25(6):313-6. PubMed ID: 25794162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.
    Cabaleiro T; Prieto-Pérez R; Navarro R; Solano G; Román M; Ochoa D; Abad-Santos F; Daudén E
    Pharmacogenomics J; 2016 Aug; 16(4):336-40. PubMed ID: 26194362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations.
    El-Shabrawi Y; Wegscheider BJ; Weger M; Renner W; Posch U; Ulrich S; Ardjomand N; Hermann J
    Ophthalmology; 2006 Apr; 113(4):695-700. PubMed ID: 16581430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eosinophilia during psoriasis treatment with TNF antagonists.
    Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
    Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNFAIP3 and IL12B gene polymorphisms associated with psoriasis vulgaris in an Egyptian cohort.
    Haase O; Mosaad H; Eldarouti MA; Elramly AZ; Samir N; Abdelhady MM; Samir M; El-Gharib I; Salah S; El-Shennawy FA; Mosaad Y; Elwan N; Salem H; Abdelgaber S; Recke A; Möller S; Zillikens D; Ibrahim S
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1297-301. PubMed ID: 25406098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viewpoint on handling anti-TNF failure in psoriasis.
    Bracke S; Lambert J
    Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
    Cho YT; Chen CH; Chiu HY; Tsai TF
    J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
    Alsharqi A; Parslew R; Dever B; Arslanian V
    Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.